DOW JONES21,076.85-840.31 -3.83%
S&P 5002,479.59-105.00 -4.06%
NASDAQ7,429.99-270.11 -3.51%

H.C. Wainwright Maintains Buy on Rubius Therapeutics, Lowers Price Target to $28

H.C. Wainwright maintains Rubius Therapeutics (NASDAQ:RUBY) with a Buy and lowers the price target from $40 to $28.

Benzinga · 03/13/2020 12:44

H.C. Wainwright maintains Rubius Therapeutics (NASDAQ:RUBY) with a Buy and lowers the price target from $40 to $28.